$791 A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with relapsed or refractory classic hodgkin lymphoma (cHL)$

791 A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with relapsed or refractory classic hodgkin lymphoma (cHL)

Bibliographic Details
Main Authors:	Hui Zhou, Jun Zhu, Xiaoling Li, Fei Li, Lei Fan, Lihong Liu, Zheng Zhao, Bing Chen, Qingyuan Zhang, Yuqin Song, Keshu Zhou, Chuan Jin, Zhengzi Qian, Ming Hou, Kaiyang Ding, Xiuhua Sun, Xianmin Song, Ming Jiang, Yu Hu, Ligen Liu, Hongwei Xue, Jun Luo, Bai He, Maxwell Wang
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2020-11-01
Series:	Journal for ImmunoTherapy of Cancer

791 A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with relapsed or refractory classic hodgkin lymphoma (cHL)

Similar Items